XML 14 R5.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Operating Expenses:    
Research and development $ 17,680 $ 9,253
General and administrative 11,370 9,892
Operating expenses 29,050 19,145
Operating loss (29,050) (19,145)
Other income (expense):    
Investment income, net 151 132
Other expense, net (75) 0
Total other income 76 132
Net loss before benefit from income taxes and noncontrolling interests (28,974) (19,013)
Benefit from income taxes (1,508) (10,872)
Net loss (27,466) (8,141)
Less - net income attributable to noncontrolling interests 0 9
Net loss attributable to Caladrius Biosciences, Inc. common shareholders $ (27,466) $ (8,150)
Basic and diluted loss per share:    
Caladrius Biosciences, Inc. common shareholders - basic (in dollars per share) $ (0.50) $ (0.53)
Caladrius Biosciences, Inc. common shareholders - diluted (in dollars per share) $ (0.50) $ (0.53)
Weighted average common shares outstanding:    
Basic shares 55,313 15,440
Diluted shares 55,313 15,440